Products

Adjuvant

Using Magic Mouse Adjuvant

Cat. No Product Name Unit Size Datasheet Price
CDN-A001 Magic Mouse Adjuvant 1mL PDF pdf Inquiry
CDN-A001E Magic Mouse Adjuvant, Enhanced 1mL PDF pdf Inquiry

Description

Magic™ Mouse Adjuvant is a novel immunization adjuvant specifically designed for rapid production of high titers of antibodies in mice. The adjuvant contains immune-stimulatory CpG DNA-short oligodeoxynucleotide that contain unmethylated cytosine-guanine dinucleotides. It is by far the most efficient mouse adjuvant for all types of immunogens tested, in terms of its rapidness in raising immune responses and the antibody tiers it produces. Magic™ Mouse Adjuvant, Enhanced is the modified versions of magic mouse adjuvant, incorporating additional immunostimulating reagents, to broaden the immune response profile to more antigens.

Features of Magic Mouse Adjuvant

  • Highly effective—rapid production of high titers of antibodies.
  • Easy to use—No emulsion step required.
  • Safe—non-toxic adjuvant with no adverse side effects to animals.
  • Immunogen saving—much less immunogen required than with conventional methods.
  • Time saving—strong immune responses can be reached within 35 days after immunization.
  • Extremely valuable-in producing antibodies against conformational epitopes.

View More

Adjuvants are substances that can accelerate, prolong, or enhance antigen-specific immune responses. As crucial components of vaccines, adjuvants can improve vaccine efficacy and/or modulate immune responses types of the co-inoculated antigen. Adjuvants employ several mechanisms to modulate immune response of a specific antigen, such as formation of depot, sustained release of antigen, up-regulation of cytokines and chemokines, increase antigen uptake and presentation to antigen presenting cells (APC), as well as activation and maturation of APC.

Specifications

Product Size: 1.0 mL

Sufficient for immunization (priming and two boosts) of up to 10 mice.

Contents & Storage

Magic™ Mouse Adjuvant is supplied as a ready-to-use solution and is shipped at ambient temperature. Upon arrival, it should be stored at 2-8°C.

Note: This product is supplied for research or manufacturing applications only and is not intended for clinical use.

Material safety data sheets (MSDS)

Related Products

For Research Use Only. Not for use in diagnostic procedures.

Citations & references

  1. Edward A. Greenfield. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 2013.
  2. Martin-Martin I, Chagas A C, Guimaraes-Costa A B, et al. Immunity to LuloHya and Lundep, the salivary spreading factors from Lutzomyia longipalpis, protects against Leishmania major infection[J]. PLoS pathogens, 2018, 14(5): e1007006.
  3. Canepa G E, Molina-Cruz A, Yenkoidiok-Douti L, et al. Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission[J]. NPJ vaccines, 2018, 3.
  4. Palomo C, Mas V, Thom M, et al. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses[J]. Journal of virology, 2016, 90(11): 5485-5498.
  5. Bernardo L, Denomme G A, Shah K, et al. RhD Specific Antibodies Are Not Detectable in HLA-DRB1 Mice Challenged with Human RhD Positive Erythrocytes[J]. Advances in hematology, 2014.
    Ferreira V P, Vale V F, Pangburn M K, et al. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis[J]. Scientific reports, 2016, 6.
  6. Olga A B, Tavares D, Setiady J, et al. Antibodies and Assays for Detection of Folate Receptor 1: U.S. Patent Application 14/473,828[P]. 2014-8-29.
  7. Mendes-Sousa, Antonio F., et al. "The sand Fly salivary Protein lufaxin inhibits the early steps of the alternative Pathway of complement by Direct Binding to the Proconvertase c3b-B." Frontiers in immunology 8 (2017): 1065.
  8.  Asojo, Oluwatoyin A., et al. "Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis." PLoS neglected tropical diseases 11.3 (2017): e0005374.

Other Adjuvant

Immunobiology Grade

  • For vaccination of sensitive animals
  • Adjuvant for laboratory animals
  • Adjuvant for antibody production

Vaccine Grade

  • Adjuvants for protein-based vaccines
  • PRR Ligands-based adjuvant

DNA Vaccination

  • Genetic adjuvants
  • DNA vaccine plasmid

ROLE OF ADJUVANTS IN VACCINES & ANTIBODY PRODUCTION

Three main types of vaccine are generally employed: i) live-attenuated vaccines, ii) inactivated vaccines that are heat- or chemically- killed microorganisms and iii) sub-unit vaccines that are made from components of the pathogen such as proteins, peptides or genetic materials. Immunization or vaccines induce pathogen-specific adaptive immunity by generating memory cells against a specific pathogen. Successful vaccines for certain pathogens will likely require enhanced immune responses including Th1-cellular-mediated immunity or a more robust Th2-humoral response.

For antibody production, a strong Th2 response will be preferred. The quality of the vaccine-induced immune response or level of antibody production will depend on several factors including, the route, number and timing of administrations, the nature of the antigen and the quality of antigen presentation. This whole process is facilitated by the adjuvants. Indeed, adjuvants allow overcoming the poorly immunogenic properties of most protein, peptide and DNA vaccines (lacking natural immune triggers) or the induction of inappropriate immune responses. Thus adjuvants can be used to: i) enhance the immune response, ii) orient the immune response through modulation of the Th1/Th2 balance and iii) reduce the amount of antigen needed and the number of injections required to induce protection (antigen-dose sparing).

Inquiry Basket